全文获取类型
收费全文 | 2967篇 |
免费 | 198篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 25篇 |
儿科学 | 53篇 |
妇产科学 | 60篇 |
基础医学 | 630篇 |
口腔科学 | 41篇 |
临床医学 | 307篇 |
内科学 | 458篇 |
皮肤病学 | 56篇 |
神经病学 | 194篇 |
特种医学 | 73篇 |
外科学 | 610篇 |
综合类 | 18篇 |
一般理论 | 3篇 |
预防医学 | 186篇 |
眼科学 | 66篇 |
药学 | 254篇 |
中国医学 | 7篇 |
肿瘤学 | 132篇 |
出版年
2023年 | 14篇 |
2022年 | 33篇 |
2021年 | 74篇 |
2020年 | 19篇 |
2019年 | 66篇 |
2018年 | 71篇 |
2017年 | 28篇 |
2016年 | 51篇 |
2015年 | 57篇 |
2014年 | 86篇 |
2013年 | 118篇 |
2012年 | 144篇 |
2011年 | 183篇 |
2010年 | 77篇 |
2009年 | 85篇 |
2008年 | 131篇 |
2007年 | 110篇 |
2006年 | 131篇 |
2005年 | 149篇 |
2004年 | 146篇 |
2003年 | 138篇 |
2002年 | 121篇 |
2001年 | 16篇 |
2000年 | 16篇 |
1999年 | 13篇 |
1998年 | 27篇 |
1997年 | 22篇 |
1996年 | 23篇 |
1995年 | 15篇 |
1994年 | 14篇 |
1993年 | 27篇 |
1991年 | 13篇 |
1990年 | 13篇 |
1988年 | 13篇 |
1984年 | 21篇 |
1983年 | 20篇 |
1982年 | 18篇 |
1977年 | 20篇 |
1976年 | 13篇 |
1974年 | 13篇 |
1934年 | 22篇 |
1933年 | 16篇 |
1929年 | 17篇 |
1928年 | 12篇 |
1926年 | 12篇 |
1925年 | 22篇 |
1924年 | 41篇 |
1923年 | 56篇 |
1922年 | 56篇 |
1920年 | 17篇 |
排序方式: 共有3173条查询结果,搜索用时 15 毫秒
51.
Ercan E Tengiz I Duman C Sekuri C Aliyev E Mutlu B Ercan HE Akin M 《Journal of thrombosis and thrombolysis》2004,17(3):207-211
BACKGROUND: Matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of arterial aneurysms through increased proteolysis of extracellular matrix proteins. Increased proteolysis due to elevated matrix degrading enzyme activity in the arterial wall may act as a susceptibility factor for the development of coronary aneurysms. Plasmin strongly stimulates pro-MMP enzyme conversion to the active form. Plasmin hyperactivity due to decreased plasminogen activator inhibitor-1 (PAI-1) may cause MMP over activity and coronary aneurysms. The aim of this study was to investigate the association between PAI-1 and presence of coronary aneurysms. METHODS: Twenty-three patients with aneurysmal coronary artery disease and stable angina were enrolled into study (Group 1). Twenty-two patients without coronary aneurysm were selected as a control group (Group 2). PAI-1 was measured in peripheral venous blood. RESULTS: The plasma PAI-1 level was lower in the coronary artery aneurysmatic patients compared to the control group (8.41 +/- 4.28 vs. 13.32 +/- 10.05 ng/ml, p = 0.037). Serum C-reactive protein (CRP) values were not significantly different between groups (3.83 +/- 1.08 vs. 4.01 +/- 1.35 mg/l, p >0.05). CONCLUSION: Increased matrix degrading enzyme activity can cause arterial wall destruction through increased proteolysis of extracellular matrix proteins. Unregulated plasmin hyperactivity due to decreased inhibition by PAI-1 may play an important role in coronary aneurysm formation. 相似文献
52.
Renal cell therapy is associated with dynamic and individualized responses in patients with acute renal failure 总被引:4,自引:0,他引:4
BACKGROUND: Renal cell therapy in conjunction with continuous hemofiltration techniques may provide important cellular metabolic activities to patients with acute renal failure (ARF) and may thereby change the natural history of this disorder. The development of a tissue-engineered bioartificial kidney consisting of a conventional hemofiltration cartridge in series with a renal tubule assist device (RAD) containing 10(9) human renal proximal tubule cells provides an opportunity to evaluate this form of therapy in patients with ARF in the intensive care unit. METHODS: Nine patients with ARF and multi-organ systems failure (MOSF) have been treated so far with a tissue-engineered kidney in an FDA-approved Phase I/II clinical study currently underway. Acute physiologic parameters and serum cytokine levels were assessed before, during and after treatment with a bioartificial kidney. RESULTS: Use of the RAD in this clinical setting demonstrates maintenance of cell viability and functionality. Cardiovascular stability appears to be maintained during RAD treatment. Human tubule cells in the RAD demonstrated differentiated metabolic and endocrinologic activity. Acute physiologic and plasma cytokine data demonstrate that renal cell therapy is associated with rapid and variable responses in patients with ARF and MOSF. CONCLUSION: The initial clinical experience with the bioartificial kidney and the RAD suggests that renal tubule cell therapy may provide a dynamic and individualized treatment program as assessed by acute physiologic and biochemical indices. 相似文献
53.
Anthony N. Vomund Cheryl F. Lichti Orion J. Peterson Ana Maria Arbelaez Xiaoxiao Wan Emil R. Unanue 《The Journal of experimental medicine》2021,218(6)
Assessing the self-peptides presented by susceptible major histocompatibility complex (MHC) molecules is crucial for evaluating the pathogenesis and therapeutics of tissue-specific autoimmune diseases. However, direct examination of such MHC-bound peptides displayed in the target organ remains largely impractical. Here, we demonstrate that the blood leukocytes from the nonobese diabetic (NOD) mice presented peptide epitopes to autoreactive CD4 T cells. These peptides were bound to the autoimmune class II MHC molecule (MHC-II) I-Ag7 and originated from insulin B-chain and C-peptide. The presentation required a glucose challenge, which stimulated the release of the insulin peptides from the pancreatic islets. The circulating leukocytes, especially the B cells, promptly captured and presented these peptides. Mass spectrometry analysis of the leukocyte MHC-II peptidome revealed a series of β cell–derived peptides, with identical sequences to those previously identified in the islet MHC-II peptidome. Thus, the blood leukocyte peptidome echoes that found in islets and serves to identify immunogenic peptides in an otherwise inaccessible tissue. 相似文献
54.
Edina A. Wappler Péter Antal Szabolcs Várbíró Béla Székács Andrea Simon Zoltán Nagy Emil Monos György L. Nádasy 《Mechanisms of ageing and development》2013,134(7-8):307-313
AimsTo identify the geometrical alterations in the age-remodeled rat coronary artery network and to develop a useful technique to analyze network properties in the rat heart.Methods and resultsWe analyzed the networks of the left anterior descendent coronary arteries on in situ perfused hearts of young (3 months) and old (18 months) male rats. All segments and branching over >80 μm diameter were analyzed using 50 μm long cylindrical ring units of the networks. Arterial widening and paucity, increased tortuosity were typical features in the old network. In addition, axis angles deviated more from the mother branches in the old, whereas the diameters of daughter branches fit the Murray law in both groups. The detected changes in the old network resulted in a longer blood flow route for the same direct distance.ConclusionWe developed a useful method to investigate arterial network property changes in the rat heart. Ageing resulted in longer, more tortuous flow route in the LAD network that might be hemodynamically disadvantageous. 相似文献
55.
Line Lykke Andersen Nanna M?rk Line S. Reinert Emil Kofod-Olsen Ryo Narita Sofie E. J?rgensen Kristian A. Skipper Klara H?ning Hans Henrik Gad Lars ?stergaard Torben F. ?rntoft Veit Hornung S?ren R. Paludan Jacob Giehm Mikkelsen Takashi Fujita Mette Christiansen Rune Hartmann Trine H. Mogensen 《The Journal of experimental medicine》2015,212(9):1371-1379
56.
John S. Millar Gissette Reyes-Soffer Patricia Jumes Richard L. Dunbar Emil M. deGoma Amanda L. Baer Wahida Karmally Daniel S. Donovan Hashmi Rafeek Laura Pollan Junichiro Tohyama Amy O. Johnson-Levonas John A. Wagner Stephen Holleran Joseph Obunike Yang Liu Rajasekhar Ramakrishnan Michael E. Lassman David E. Gutstein Henry N. Ginsberg Daniel J. Rader 《The Journal of clinical investigation》2015,125(6):2510-2522
BACKGROUND. Individuals treated with the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibit a reduction in both LDL cholesterol and apolipoprotein B (ApoB) in response to monotherapy or combination therapy with a statin. It is not clear how anacetrapib exerts these effects; therefore, the goal of this study was to determine the kinetic mechanism responsible for the reduction in LDL and ApoB in response to anacetrapib.METHODS. We performed a trial of the effects of anacetrapib on ApoB kinetics. Mildly hypercholesterolemic subjects were randomized to background treatment of either placebo (n = 10) or 20 mg atorvastatin (ATV) (n = 29) for 4 weeks. All subjects then added 100 mg anacetrapib to background treatment for 8 weeks. Following each study period, subjects underwent a metabolic study to determine the LDL-ApoB-100 and proprotein convertase subtilisin/kexin type 9 (PCSK9) production rate (PR) and fractional catabolic rate (FCR).RESULTS. Anacetrapib markedly reduced the LDL-ApoB-100 pool size (PS) in both the placebo and ATV groups. These changes in PS resulted from substantial increases in LDL-ApoB-100 FCRs in both groups. Anacetrapib had no effect on LDL-ApoB-100 PRs in either treatment group. Moreover, there were no changes in the PCSK9 PS, FCR, or PR in either group. Anacetrapib treatment was associated with considerable increases in the LDL triglyceride/cholesterol ratio and LDL size by NMR.CONCLUSION. These data indicate that anacetrapib, given alone or in combination with a statin, reduces LDL-ApoB-100 levels by increasing the rate of ApoB-100 fractional clearance.TRIAL REGISTRATION. ClinicalTrials.gov .FUNDING. Merck & Co. Inc., Kenilworth, New Jersey, USA. Additional support for instrumentation was obtained from the National Center for Advancing Translational Sciences (UL1TR000003 and UL1TR000040). NCT00990808相似文献
57.
Carlo Alberto Barcella Morten Lamberts Patricia McGettigan Emil Loldrup Fosbl Jesper Lindhardsen Christian Torp‐Pedersen Gunnar Hilmar Gislason Anne‐Marie Schjerning Olsen 《Basic & clinical pharmacology & toxicology》2019,124(5):629-641
Osteoarthritis (OA) and the non‐steroidal anti‐inflammatory drugs (NSAIDs) used to relieve OA‐associated pain have been linked independently to increased cardiovascular risk. We examined the risk of cardiovascular events associated with NSAID use in patients with OA. We employed linked nationwide administrative registers to examine NSAID use between 1996 and 2015 by Danish patients with OA aged ≥18 years. Using adjusted Cox proportional hazard analyses, we calculated the risk of the composite outcome of cardiovascular death, non‐fatal myocardial infarction and non‐fatal ischaemic stroke/TIA, and of each outcome separately, up to 5 years after OA diagnosis. Of 533 502 patients included, 64.3% received NSAIDs and 38 226 (7.2%) experienced a cardiovascular event during follow‐up. Compared with non‐use, all NSAIDs were associated with increased risk of the composite outcome: hazard ratio (HR) for rofecoxib, 1.90 (95% confidence interval, 1.74‐2.08); celecoxib, 1.47 (1.34‐1.62); diclofenac, 1.44 (1.36‐1.54); ibuprofen, 1.20 (1.15‐1.25); and naproxen, 1.20 (1.04‐1.39). Similar results were seen for each outcome separately. When celecoxib was used as reference, ibuprofen (HRs: 0.81 [CI: 0.74‐0.90]) and naproxen (HRs: 0.81 [0.68‐0.97]) exhibited a lower cardiovascular risk, even when low doses were compared. Low‐dose naproxen and ibuprofen were associated with the lowest risks of the composite outcome compared to no NSAID use: HRs: 1.12 (1.07‐1.19) and 1.16 (0.92‐1.42), respectively. In patients with OA, we found significant differences in cardiovascular risk among NSAIDs. Naproxen and ibuprofen appeared to be safer compared to celecoxib, also when we examined equivalent low doses. In terms of cardiovascular safety, naproxen and ibuprofen, at the lowest effective doses, may be the preferred first choices among patients with OA needing pain relief. 相似文献
58.
59.
Fosbol EL Wang TY Li S Piccini JP Lopes RD Shah B Mills RM Klaskala W Alexander KP Thomas L Roe MT Peterson ED 《American heart journal》2012,163(4):720-728
60.